Kami Kim of USF has joined the national Prevent COVID U randomized control trial to study how well the COVID-19 vaccine prevents the spread of the virus among young adults aged 18 to 29. This age group currently has the lowest vaccination rate among all adults.
“This study has implications for public health guidance as new COVID-19 variants continue to emerge,” said Kim. “It will help us answer critical questions about whether a person can become infected after vaccination, and if the vaccine will stop the virus from spreading to others.”
View Related Expert Profiles: Go to Source
